HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target
AbstractUveal melanoma (UM) is the most common primary intraocular malignancy in adults, and gives rise to metastases in 50% of cases. The presence of an inflammatory phenotype is a well-known risk factor for the development of metastases. This inflammatory phenotype is characterized by the presence of high numbers of lymphocytes and macrophages, and a high expression of the HLA Class I and II antigens. An abnormal expression of HLA Class I may influence cytotoxic T lymphocyte (CTL) as well as Natural Killer (NK) cell responses. We provide a comprehensive review regarding the inflammatory phenotype in UM and the expression of locus- and allele-specific HLA Class I and of Class II antigens in primary UM and its metastases. Furthermore, we describe the known regulators and the role of genetics (especially chromosome 3 and BRCA-Associated Protein 1 (BAP1 status)), and, last but not least, the effect of putative therapeutic treatments on HLA expression. View Full-Text
Share & Cite This Article
Souri, Z.; Wierenga, A.P.; Mulder, A.; Jochemsen, A.G.; Jager, M.J. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target. Cancers 2019, 11, 1132.
Souri Z, Wierenga AP, Mulder A, Jochemsen AG, Jager MJ. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target. Cancers. 2019; 11(8):1132.Chicago/Turabian Style
Souri, Zahra; Wierenga, Annemijn P.; Mulder, Arend; Jochemsen, Aart G.; Jager, Martine J. 2019. "HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target." Cancers 11, no. 8: 1132.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.